AKI Matched Phenotype Linked Evaluation with Tissue (AMPLE-Tissue)
AKI 匹配表型相关组织评估 (AMPLE-Tissue)
基本信息
- 批准号:9911045
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Renal Failure with Renal Papillary NecrosisAnimal ModelAnimalsBiopsyBrain DeathCessation of lifeClinicalClinical TrialsClinical Trials Data Monitoring CommitteesCollectionCommunitiesComplexComputerized Medical RecordConsentCore BiopsyCritical IllnessDataData LinkagesData QualityDialysis procedureEnrollmentEquilibriumEthicsEtiologyEvaluationEventExcisionFamilyFundingHealth Care CostsHemorrhageHepatorenal SyndromeHistologicHospitalizationHumanHuman CharacteristicsIncidenceIntensive Care UnitsInterventionKidneyKidney DiseasesKidney TransplantationLeadLinkLiving DonorsLongterm Follow-upMedicalMedical RecordsMolecularMolecular TargetMonitorMorbidity - disease rateNephrectomyParticipantPathologyPathway interactionsPatient MonitoringPatientsPercutaneous NephrostomyPersonsPhasePhenotypePopulationProspective StudiesRenal Cell CarcinomaRenal functionReproducibilityResearchRiskRisk FactorsSafetySamplingSelection BiasSeveritiesSiteSystemTelephoneTimeTissuesTransfusionTranslational ResearchUnited States National Institutes of HealthVisitadministrative databaseadverse outcomebaseclinically significantcohortcostdata sharingelectronic dataendophenotypeexperiencefollow-uphuman diseasehuman tissuekidney biopsyliver transplantationmortalitynovelnovel markerpatient safetyprecision medicineprogramspublic health relevancerecruitresearch studyresponsespecific biomarkerstargeted treatmenttherapeutic targeturinary tract obstruction
项目摘要
Abstract
Acute kidney injury (AKI) is a common condition and is associated with both short- and long-term adverse
outcomes in those who develop it. Translational research studies of actual human kidney tissue during an AKI
event can lead to discovery of novel AKI pathways and therapeutic targets.
In response to the RFA-DK-16-026, also known as the Kidney Precision Medicine Program, our proposal aims
to safely and ethically enroll a diverse group of participants with AKI. Our proposal aims to balance the need
for obtaining kidney tissue from a diverse AKI population with the risks of obtaining this tissue. Kidney biopsies
carry a small but significant risk of bleeding which may be somewhat increased in the setting of AKI.
In the AKI Matched Phenotype Linked Evaluation with Tissue (AMPLE-Tissue) Study, we propose that the
optimal way to obtain tissue in AKI patients would be through a combination of approaches. First, we will obtain
extra tissue at the time of clinically indicated kidney biopsies, since prior data suggests that this approach does
not add additional bleeding risk. We will carefully select participants who are at lower risk of bleeding. Over the
last two years, we have enrolled over 200 participants in a research study and collected kidney biopsies from
them. Over 70% of these participants said that they would be willing to donate extra tissue for research.
Second, to encompass the whole AKI spectrum from its mildest to severest forms, we will also biopsy kidneys
in deceased donors. The causes of AKI in deceased donors are similar to those experienced by critically ill AKI
patients. Obtaining biopsies in this setting is low-risk; we have successfully enrolled over 900 deceased
patients who received kidney biopsies in an ongoing NIH-funded project. Third, we will obtain research-only
biopsies in specially-selected settings of hepatorenal syndrome and obstructive kidney disease when bleeding
risk is low.
In the UG3 phase, our aim is to obtain biopsies from 90-100 participants over two years and closely monitor
patient safety. We will establish a community advisory board of AKI patients in addition to a data and safety
monitoring board for the study. We will share data within the consortium after removal of patient identifiers. We
will also establish linkages with various electronic medical record system as well as administrative databases
to streamline follow-up. In the UH3 phase, we will expand our study to other sites and settings based on the
biopsy quality and safety data from UG3 phase and enroll 375 participants over three years. We will also
conduct longitudinal follow-up on all participants using various mechanisms which were effective for us in the
past.
摘要
急性肾损伤(AKI)是一种常见的疾病,与短期和长期的不良反应有关。
结果发生在那些发展它的人身上。急性肾移植中人肾组织的翻译研究
事件可以导致新的AKI途径和治疗靶点的发现。
为了响应RFA-DK-16-026,也被称为肾脏精准医学计划,我们的提案旨在
以安全和合乎道德的方式为不同群体的参与者注册AKI。我们的建议旨在平衡这一需求
从有获取肾组织风险的不同AKI人群中获取肾组织。肾活检
有少量但严重的出血风险,在AKI的情况下可能会有所增加。
在AKI匹配表型评估与组织(充分组织)研究中,我们建议
获取AKI患者组织的最佳方法是通过多种方法的组合。首先,我们将获得
临床指征的肾脏活检时的额外组织,因为先前的数据表明这种方法有
不会增加额外的出血风险。我们将仔细挑选出血风险较低的参与者。超过了
在过去的两年里,我们招募了200多名参与者参加一项研究,并从
他们。超过70%的参与者表示,他们愿意捐赠额外的组织用于研究。
其次,为了涵盖从最轻到最重的AKI的整个谱系,我们还将对肾脏进行活检
在已故捐赠者身上。已故供者发生急性KI的原因与病情危重的AKI相似。
病人。在这种情况下获得活组织检查的风险很低;我们已经成功地招募了900多名死者
在NIH资助的一个正在进行的项目中接受肾脏活检的患者。第三,我们将只获取研究报告
肝肾综合征和梗阻性肾病出血时的特殊情况下的活检
风险很低。
在UG3阶段,我们的目标是在两年内从90-100名参与者那里获得活组织检查,并密切监测
病人安全。除了数据和安全,我们还将建立一个AKI患者的社区咨询委员会
这项研究的监督委员会。删除患者身份标识后,我们将在财团内共享数据。我们
还将与各种电子病历系统以及行政数据库建立联系
以简化后续工作。在UH3阶段,我们会将研究扩展至其他地点和环境,以
来自UG3阶段的活检质量和安全数据,并在三年内招募了375名参与者。我们还将
使用各种机制对所有参与者进行纵向跟踪,这些机制对我们在
过去时。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chirag R Parikh其他文献
Attempts To Achieve Standardized Definitions To Characterize Changes In Kidney Function In The Context Of Heart Failure Clinical Trials: From The Heart Failure Collaboratory
在心力衰竭临床试验中尝试实现标准化定义以表征肾功能变化:来自心力衰竭协作组
- DOI:
10.1016/j.cardfail.2024.10.106 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:8.200
- 作者:
Isabella Cavagna;Anu Lala;Carine Hamo;Mona Fiuzat;Steven Coca;William Abraham;Christopher O'Connor;JoAnn Lindenfeld;James Januzzi;Mark Sarnak;Chirag R Parikh;Wendy McCallum;Marvin Konstam;Maria Rosa Costanzo - 通讯作者:
Maria Rosa Costanzo
Reversal of end-stage renal disease after aortic dissection using renal artery stent: a case report
- DOI:
10.1186/1471-2369-5-7 - 发表时间:
2004-05-04 - 期刊:
- 影响因子:2.400
- 作者:
Andrew S Weiss;Michael Ludkowski;Chirag R Parikh - 通讯作者:
Chirag R Parikh
Chirag R Parikh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chirag R Parikh', 18)}}的其他基金
Post-Discharge Nephrology Follow-up for Improved Outcomes
出院后肾脏病学随访以改善结果
- 批准号:
10451808 - 财政年份:2021
- 资助金额:
$ 30万 - 项目类别:
Post-Discharge Nephrology Follow-up for Improved Outcomes
出院后肾脏病学随访以改善结果
- 批准号:
10296363 - 财政年份:2021
- 资助金额:
$ 30万 - 项目类别:
Post-Discharge Nephrology Follow-up for Improved Outcomes
出院后肾脏病学随访以改善结果
- 批准号:
10670199 - 财政年份:2021
- 资助金额:
$ 30万 - 项目类别:
AKI Matched Phenotype Linked Evaluation with Tissue (AMPLE-Tissue)
AKI 匹配表型相关组织评估 (AMPLE-Tissue)
- 批准号:
10225441 - 财政年份:2018
- 资助金额:
$ 30万 - 项目类别:
AKI Matched Phenotype Linked Evaluation with Tissue (AMPLE-Tissue)
AKI 匹配表型相关组织评估 (AMPLE-Tissue)
- 批准号:
10493566 - 财政年份:2017
- 资助金额:
$ 30万 - 项目类别:
AKI Matched Phenotype Linked Evaluation with Tissue (AMPLE-Tissue)
AKI 匹配表型相关组织评估 (AMPLE-Tissue)
- 批准号:
10703455 - 财政年份:2017
- 资助金额:
$ 30万 - 项目类别:
Novel Kidney Injury Tools in Deceased Organ Donation to Predict Graft Outcomes
死亡器官捐赠中预测移植结果的新型肾损伤工具
- 批准号:
10177020 - 财政年份:2012
- 资助金额:
$ 30万 - 项目类别:
Novel Kidney Injury Tools in Deceased Organ Donation to Predict Graft Outcome
死亡器官捐赠中预测移植结果的新型肾损伤工具
- 批准号:
8370601 - 财政年份:2012
- 资助金额:
$ 30万 - 项目类别:
Mentoring Program for Translational and Patient Oriented Research in AKI
AKI 转化和以患者为导向的研究指导计划
- 批准号:
8607937 - 财政年份:2012
- 资助金额:
$ 30万 - 项目类别:
Novel Kidney Injury Tools in Deceased Organ Donation to Predict Graft Outcome
死亡器官捐赠中预测移植结果的新型肾损伤工具
- 批准号:
9233645 - 财政年份:2012
- 资助金额:
$ 30万 - 项目类别: